Aim:

To describe the outcomes in a group of patients with neuroendocrine tumors (NETs) of the small intestine treated in a multidisciplinary group.

Methods:

A descriptive study based on the clinical records of patients with confirmed histological diagnosis of a neuroendocrine tumor with intestinal primary between 1 May 2004 and 30 April 2014

Results:

A total of 301 patients diagnosed with NETs in different locations were treated during the study period, of which 48 cases of intestinal primary met the inclusion criteria.

Surgery with curative or palliative intent was the first line of treatment in most patients (n = 35, 72.9%) and complete remission was achieved in 13 of them. Somatostatin analogues were the first line of management in 14.5%.

At the time of the last assessment, 13 patients (27.1%) remained disease-free, 17 patients (35.4%) with persistent but stable disease, and 7 patients (14.6%) had progressive disease. More than 50% of the patients remained alive at 55 months after diagnosis.

The higher age at diagnosis, the presence of carcinoid syndrome, the metastatic compromise, the histological grade, and elevated biochemical markers (Chromogranin A and 5-hydroxy indole acetic acid) were factors associated with a worse survival prognosis.

Conclusions:

A summary is presented on the clinical outcomes of the treatment of patients with NET of primary intestinal by a multidisciplinary group, as well as the comparison of these outcomes with the data available in the literature.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )